Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 7 min read

SS-31 (Elamipretide) vs 5-Amino-1MQ: what the research actually compares

A research-only comparison of SS-31 (elamipretide) and 5-amino-1MQ: what each compound is, what published studies measured, where the evidence is stronger, and what remains unknown.

peptides-pro Editorial

SS-31, also known as elamipretide, is a synthetic tetrapeptide with alternating cationic and aromatic residues that binds the mitochondrial inner membrane; it is studied as a mitochondria-targeted therapeutic peptide [2]. 5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that consumes S-adenosylmethionine and produces 1-methylnicotinamide; the compound is used in laboratory research to probe NNMT-dependent methylation and NAD+ metabolism. The evidence block for this comparison does not provide a sequence, formula, or molecular weight for either compound, so none are stated here.

The published work on SS-31 centres on mitochondrial inner-membrane binding, oxidative stress reduction, and bioenergetic function [2], with clinical programmes in Barth syndrome, primary mitochondrial myopathy, dry age-related macular degeneration, and healthy aging [3][5][7][8]. The published work on 5-amino-1MQ centres on NNMT inhibition and its downstream effects on cellular methylation and energy metabolism; the evidence block supplied for this page does not include primary studies of 5-amino-1MQ, so the comparison below is limited to what the SS-31 literature reports and to the mechanistic distinction between the two compounds.

Research Studies

SS-31 (Elamipretide) and radiation-induced cardiomyocyte senescence

A study in cardiomyoblast H9C2 cells and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) evaluated the mitochondrial-targeted peptide SS-31 (elamipretide) against radiation-induced cell senescence [1]. Exposure to γ-radiation at 2, 5, and 10 Gy inhibited H9C2 proliferation in a dose-dependent manner and induced senescence-associated beta-galactosidase (SA-β-gal) staining [1]. The study reported that SS-31 attenuated these senescence markers in the cell models tested [1].

SS-31 (Elamipretide) and α-synuclein membrane binding and mitochondrial function

In a study of α-synuclein, a protein associated with Parkinson's disease and related synucleinopathies, SS-31 was examined for its ability to modulate α-synuclein interaction with lipid membranes and to mitigate mitochondrial impairment induced by α-synuclein oligomers [2]. Using fluorescence correlation spectroscopy and fluorescence anisotropy, the study demonstrated that SS-31 displaces both wild-type and N-terminally acetylated α-synuclein from membranes [2]. The work describes SS-31 as a therapeutic tetrapeptide with known mitochondrial inner membrane binding and oxidative stress reduction properties [2].

SS-31 (Elamipretide) and Barth syndrome: clinical trial

A Phase 3b/4 randomized, double-blind, parallel-group, placebo-controlled trial is evaluating once-daily subcutaneous elamipretide in subjects with genetically confirmed Barth syndrome (BTHS) over 72 weeks [3]. The primary objective is to confirm efficacy of elamipretide, which is approved in the United States under accelerated approval based on improvement in knee extensor muscle strength, an intermediate clinical endpoint [3].

SS-31 (Elamipretide) and primary mitochondrial myopathy from nuclear DNA mutations

SPIMD-301 is a 48-week randomized, double-blind, parallel-group, placebo-controlled trial assessing efficacy and safety of single daily subcutaneous elamipretide in subjects with primary mitochondrial myopathy associated with nuclear DNA mutations (nPMD) [8].

SS-31 (Elamipretide) and dry age-related macular degeneration

The ReNEW Phase 3 study is evaluating efficacy, safety, and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (dry AMD) [7]. Participants receive either once-daily subcutaneous doses of 40 mg elamipretide or placebo, and the main questions concern the rate of change in the macular area of photoreceptor loss and the safety and tolerability of daily subcutaneous injections [7].

SS-31 (Elamipretide) and healthy aging and physical function

A study of healthy aging and physical function with elamipretide plans to administer a daily dose for 4 weeks and screen sufficient subjects to enroll 30 participants [5]. The planned duration includes baseline measurement, a 4-week intervention period, a midpoint check-in phone interview at 2 weeks ±3 days, post-intervention visits mirroring baseline, and a 2-week follow-up period concluded by an end-of-study contact [5].

SS-31 (Elamipretide) and expanded access

An intermediate-size expanded access protocol for elamipretide states that the treating physician must contact the sponsor using the provided contacts, and that elamipretide will only be made available after careful review of an individual request submitted by the treating physician [6]. The protocol notes that initiation and conduct of treatment, and compliance with the treatment guideline, are under the full and sole responsibility of the treating physician [6].

SS-31 (Elamipretide) in aged female mice under nutritional stress

A comparative study in aged female mice under nutritional stress evaluated mitochondria-targeted compounds, including MitoQ and SS-31 (elamipretide), in the context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [9]. The study reports that early mitochondrial dysfunction drives lipid imbalance, inflammation, and fibrosis, and notes the lack of approved pharmacological treatments for MASLD [9].

SS-31 (Elamipretide) and mitochondrial oxidative stress in traumatic brain injury

A time-resolved proteomics study in mouse brains after controlled cortical impact examined whether seawater immersion amplifies pathology or reshapes the temporal trajectory of post-traumatic biology, and identified mitochondrial oxidative stress as a modifiable therapeutic target [11].

SS-31 (Elamipretide) and mitochondrial dysfunction in gestational diabetes mellitus

A review of redox imbalance and mitochondrial dysfunction in gestational diabetes mellitus (GDM) describes impaired oxidative phosphorylation in the placenta, increased reactive oxygen species (ROS) production, and insufficient antioxidant protection as factors that impair bioenergetics and affect maternal-foetal nutrient exchange [4]. The review notes that such changes promote excessive foetal growth and metabolic programming while predisposing mothers to future type 2 diabetes, and that alterations in mitochondrial dynamics and mitophagy are additional risk factors for placental disease [4].

SS-31 (Elamipretide) and rheumatoid arthritis

A study of engineered mitochondria-targeted biomimetic hybrid nanovesicles in rheumatoid arthritis (RA) reports that mitochondrial dysfunction and abnormal activation of the cGAS-STING signalling pathway play a key role in RA, and that the nanovesicles ameliorate RA via regulating macrophage autophagy and cGAS-STING signalling [10].

What the published work measured for each compound

CompoundClassPrimary mechanism studiedModels or populations in the evidence blockMeasured outcomes reported
SS-31 (Elamipretide)Mitochondria-targeted tetrapeptideMitochondrial inner membrane binding; oxidative stress reduction; bioenergetic function [2]H9C2 cardiomyoblasts and hiPSC-CMs [1]; α-synuclein membrane systems [2]; Barth syndrome [3]; nPMD [8]; dry AMD [7]; healthy aging [5]; expanded access [6]; aged female mice under nutritional stress [9]; mouse TBI [11]; GDM review [4]; RA nanovesicle study [10]SA-β-gal staining and proliferation in H9C2 [1]; α-synuclein displacement from membranes [2]; knee extensor muscle strength (intermediate endpoint) [3]; rate of change in macular area of photoreceptor loss [7]; safety and tolerability [7]
5-Amino-1MQSmall-molecule NNMT inhibitorNNMT inhibition; downstream effects on methylation and NAD+ metabolismNot specified in the evidence blockNot specified in the evidence block

Where the evidence is stronger for one

The evidence block contains multiple clinical trial records for SS-31 (elamipretide), including Phase 3 and Phase 3b/4 studies in Barth syndrome, nPMD, and dry AMD, as well as a healthy aging study and an expanded access protocol [3][5][6][7][8]. These records describe randomized, double-blind, placebo-controlled designs and specify endpoints such as knee extensor muscle strength and rate of change in macular photoreceptor loss [3][7]. For 5-amino-1MQ, the evidence block supplied for this page contains no primary studies, no clinical trial records, and no measured outcomes. On the basis of the evidence block alone, the published work on SS-31 is more extensive and includes human trial designs, while the published work on 5-amino-1MQ is not represented.

What is simply not known

The evidence block does not provide a sequence, formula, or molecular weight for either compound, so no structural comparison can be made here. It does not provide pharmacokinetic data for 5-amino-1MQ, nor any study reporting its effects in cells, animals, or humans. It does not provide head-to-head studies comparing SS-31 and 5-amino-1MQ. For SS-31, the evidence block includes trial records and preclinical studies, but it does not provide final results for the ongoing trials, and it does not establish efficacy for any indication beyond the intermediate endpoint noted for Barth syndrome [3]. The evidence block also does not address whether findings in one model or population generalize to another.

If you are reading this for personal health reasons

The materials described here are sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp